Sativex Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Sativex General Information
Description
Developer of a pharmaceutical therapeutic drug designed for symptom management in neurological conditions. The company's platform delivers a cannabinoid-based oral spray with targeted dosing and clinical monitoring features, enabling adult patients with multiple sclerosis to achieve clinically meaningful relief from moderate to severe spasticity.
Contact Information
Corporate Office
- United Kingdom
Corporate Office
- United Kingdom
Sativex Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sativex Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sativex FAQs
-
Where is Sativex headquartered?
Sativex is headquartered in United Kingdom.
-
What industry is Sativex in?
Sativex’s primary industry is Drug Discovery.
-
Is Sativex a private or public company?
Sativex is a Private company.
-
What is Sativex’s current revenue?
The current revenue for Sativex is .
-
Who are Sativex’s investors?
Jazz Pharmaceuticals has invested in Sativex.
-
When was Sativex acquired?
Sativex was acquired on 30-Oct-2025.
-
Who acquired Sativex?
Sativex was acquired by CNX Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process